Concepedia

Joerg Frei

JF

Statistics

Publications

6

Citations

1.2K

H-Index

6

Active since

1991

Affiliations

Novartis (Switzerland)(Current)

Joerg Frei is an author at Novartis (Switzerland) specializing in pharmacology, medicinal chemistry, and medicine.

Publications per year

1991–2003

6

Publications

6

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

, , +16

Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors:  4-(Phenylamino)pyrazolo[3,4-<i>d</i>]pyrimidines

Peter Traxler, Guido Bold, Joerg Frei et al. · Journal of Medicinal Chemistry · 1997 · 205 citations · Full text

, , +17

Evaluation of desferrithiocin and its synthetic analogs as orally effective iron chelators

Raymond J. Bergeron, Jan Wiegand, John B. Dionis et al. · Journal of Medicinal Chemistry · 1991 · 86 citations

, , +17

2-Substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity

Jaroslav Staněk, Joerg Frei, Helmut Mett et al. · Journal of Medicinal Chemistry · 1992 · 54 citations · Full text

, , +8

CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis

Guido Bold, Joerg Frei, Pascal Furet et al. · Drugs of the Future · 2002 · 18 citations

, , +16

1–5 of 6